CAS Number: 1374639-75-4

Stage: Under development/Pilot trials/validation

Ribociclib Succinate is the succinate salt of Ribociclib, a CDK4/6 inhibitor indicated for HR+/HER2- advanced or metastatic breast cancer. When used in combination with endocrine therapy, Ribociclib Succinate effectively slows cancer progression by targeting cell cycle pathways. It is a cornerstone of targeted cancer therapy in the hormonal-positive breast cancer segment. Explore Royal Pharma as your potential partner for Ribociclib Succinate API.